Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review

References

• Bahn RS, Heufelder AE, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329(20):1468–1475. doi:10.1056/NEJM199311113292007
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML. Graves’ ophthalmopathy. N Engl J Med. 2009;360(10):994–1001. doi:10.1056/NEJMcp0806317
   PubMed Web of Science ®Google Scholar
• Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–738. doi:10.1056/NEJMra0905750
   PubMed Web of Science ®Google Scholar
• Currò N, Covelli D, Vannucchi G, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014;24(5):897–905. doi:10.1089/thy.2013.0445
   PubMed Web of Science ®Google Scholar
• Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf). 2005;63(3):323–328. doi:10.1111/j.1365-2265.2005.02345.x
   PubMed Web of Science ®Google Scholar
• Saeed P, Rad ST, Bisschop PH. Dysthyroid optic neuropathy. Ophthal Plast Reconstr Surg. 2018;34(4S):S60–S7. doi:10.1097/IOP.0000000000001146
   PubMedGoogle Scholar
• Bartley GB, Fatourechi V, Kadrmas EF, et al. The treatment of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(2):200–206. doi:10.1016/S0002-9394(14)70585-9
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26. doi:10.1159/000443828
   PubMed Web of Science ®Google Scholar
• Tagami M, Honda S, Azumi A. Preoperative clinical factors and visual outcomes following orbital decompression with dysthyroid optic neuropathy. BMC Ophthalmol. 2020;20(1):30. doi:10.1186/s12886-020-1314-8
   PubMed Web of Science ®Google Scholar
• Tu Y, Wu S, Pan Z, et al. Endoscopic transconjunctival deep lateral wall decompression for thyroid-associated orbitopathy: a minimally invasive alternative: transconjunctival endoscopic with wall decompression for TAO. Am J Ophthalmol. 2021;235:71–79. doi:10.1016/j.ajo.2021.08.013
   PubMed Web of Science ®Google Scholar
• Singh S, Curragh DS, Selva D. Augmented endoscopic orbital apex decompression in dysthyroid optic neuropathy. Eye (Lond). 2019;33(10):1613–1618. doi:10.1038/s41433-019-0464-5
   PubMed Web of Science ®Google Scholar
• Carter KD, Frueh BR, Hessburg TP, Musch DC. Long-term efficacy of orbital decompression for compressive optic neuropathy of Graves’ eye disease. Ophthalmology. 1991;98(9):1435–1442. doi:10.1016/S0161-6420(91)32115-8
   PubMed Web of Science ®Google Scholar
• Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181:4397–4405. doi:10.4049/jimmunol.181.6.4397
   PubMed Web of Science ®Google Scholar
• Douglas R, Naik V, Hwang C, et al. B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008;181:5768–5774. doi:10.4049/jimmunol.181.8.5768
   PubMed Web of Science ®Google Scholar
• Smith T, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019;40:236–267. doi:10.1210/er.2018-00066
   PubMed Web of Science ®Google Scholar
• Smith T, Kahaly G, Ezra D, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748–1761. doi:10.1056/NEJMoa1614949
   PubMed Web of Science ®Google Scholar
• Douglas R, Kahaly G, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341–352. doi:10.1056/NEJMoa1910434
   PubMed Web of Science ®Google Scholar
• Kahaly G, Douglas R, Holt R, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9:360–372.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–g67. doi:10.1530/EJE-21-0479
   PubMed Web of Science ®Google Scholar
• McKeag D, Lane C, Lazarus JH, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007;91(4):455–458. doi:10.1136/bjo.2006.094607
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Nakamura Y. Results of transmedial-canthal ethmoidal decompression for severe dysthyroid optic neuropathy. Jpn J Ophthalmol. 1999;43(5):426–432. doi:10.1016/S0021-5155(99)00091-X
   PubMed Web of Science ®Google Scholar
• Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol. 1978;96(7):1199–1209. doi:10.1001/archopht.1978.03910060033007
   PubMedGoogle Scholar
• Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab. 2012;26(3):273–279. doi:10.1016/j.beem.2011.10.005
   PubMed Web of Science ®Google Scholar
• Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20(7):777–783. doi:10.1089/thy.2010.1634
   PubMed Web of Science ®Google Scholar
• Okada Y, Momozawa Y, Ashikawa K, et al. Construction of a population-specific HLA imputation reference panel and its application to Graves’ disease risk in Japanese. Nat Genet. 2015;47(7):798–802. doi:10.1038/ng.3310
   PubMed Web of Science ®Google Scholar
• Huang X, Liu G, Mei S, et al. Human leucocyte antigen alleles confer susceptibility and progression to Graves’ ophthalmopathy in a Southern Chinese population. Br J Ophthalmol. 2021;105(10):1462–1468. doi:10.1136/bjophthalmol-2020-317091
   PubMed Web of Science ®Google Scholar
• Khong JJ, Finch S, De Silva C, et al. Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) study. J Clin Endocrinol Metab. 2016;101(7):2711–2720. doi:10.1210/jc.2015-4294
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee SY, Yoon JS. Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients. Korean J Ophthalmol. 2010;24(5):267–273. doi:10.3341/kjo.2010.24.5.267
   PubMedGoogle Scholar
• Deng Z, Chen L, Tan J, et al. Combination model of thyrotrophin receptor antibody and volumetric orbital apex crowding index as an indicator of dysthyroid optic neuropathy. Dis Markers. 2021;2021:9964232. doi:10.1155/2021/9964232
   PubMed Web of Science ®Google Scholar
• Kalmann R, Mourits MP. Diabetes mellitus: a risk factor in patients with Graves’ orbitopathy. Br J Ophthalmol. 1999;83(4):463–465. doi:10.1136/bjo.83.4.463
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patients. Ophthalmology. 2008;115(10):1818–1825. doi:10.1016/j.ophtha.2008.03.032
   PubMed Web of Science ®Google Scholar
• Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26(5):470–485. doi:10.1016/j.preteyeres.2007.06.001
   PubMed Web of Science ®Google Scholar
• Neigel JM, Rootman J, Belkin RI, et al. Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology. 1988;95(11):1515–1521. doi:10.1016/S0161-6420(88)32978-7
   PubMed Web of Science ®Google Scholar
• Mensah A, Vignal-Clermont C, Mehanna C, et al. Dysthyroid optic neuropathy: atypical initial presentation and persistent visual loss. Orbit. 2009;28(6):354–362. doi:10.3109/01676830903104728
   PubMedGoogle Scholar
• Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of Graves’ orbitopathy vary with age and sex. Arch Ophthalmol. 1993;111(2):197–201. doi:10.1001/archopht.1993.01090020051022
   PubMedGoogle Scholar
• Miśkiewicz P, Rutkowska B, Jabłońska A, et al. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy. Endokrynol Pol. 2016;67(2):166–173. doi:10.5603/EP.a2016.0018
   PubMed Web of Science ®Google Scholar
• Bahn RS. Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res. 2015;47(10):773–778. doi:10.1055/s-0035-1555762
   PubMed Web of Science ®Google Scholar
• Ponto KA, Diana T, Binder H, et al. Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy. J Endocrinol Invest. 2015;38(7):769–777. doi:10.1007/s40618-015-0254-2
   PubMed Web of Science ®Google Scholar
• Iyer S, Bahn R. Immunopathogenesis of Graves’ ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab. 2012;26(3):281–289. doi:10.1016/j.beem.2011.10.003
   PubMed Web of Science ®Google Scholar
• Walasik-Szemplińska D, Pauk-Domańska M, Sanocka U, Sudoł-Szopińska I. Doppler imaging of orbital vessels in the assessment of the activity and severity of thyroid-associated orbitopathy. J Ultrason. 2015;15(63):388–397. doi:10.15557/JoU.2015.0036
   PubMed Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9–14. doi:10.1046/j.1365-2265.1997.2331047.x
   PubMed Web of Science ®Google Scholar
• Soares-Welch CV, Fatourechi V, Bartley GB, et al. Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients. Am J Ophthalmol. 2003;136(3):433–441. doi:10.1016/S0002-9394(03)00233-2
   PubMed Web of Science ®Google Scholar
• Garip Kuebler A, Halfter K, Reznicek L, et al. A pathological indicator for dysthyroid optic neuropathy: tritan color vision deficiency. Graefes Arch Clin Exp Ophthalmol. 2021;259(11):3421–3426. doi:10.1007/s00417-021-05227-8
   PubMed Web of Science ®Google Scholar
• Kirsch E, von Arx G, Hammer B. Imaging in Graves’ orbitopathy. Orbit. 2009;28(4):219–225.
   PubMedGoogle Scholar
• Hu H, Xu XQ, Wu FY, et al. Diagnosis and stage of Graves’ ophthalmopathy: efficacy of quantitative measurements of the lacrimal gland based on 3-T magnetic resonance imaging. Exp Ther Med. 2016;12(2):725–729. doi:10.3892/etm.2016.3389
   PubMed Web of Science ®Google Scholar
• Mayer EJ, Fox DL, Herdman G, et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol. 2005;56(1):20–24. doi:10.1016/j.ejrad.2005.03.027
   PubMed Web of Science ®Google Scholar
• Yokoyama N, Nagataki S, Uetani M, et al. Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy. Thyroid. 2002;12(3):223–227. doi:10.1089/105072502753600179
   PubMed Web of Science ®Google Scholar
• Feldon SE, Muramatsu S, Weiner JM. Clinical classification of Graves’ ophthalmopathy: identification of risk factors for optic neuropathy. Arch Ophthalmol. 1984;102(10):1469–1472. doi:10.1001/archopht.1984.01040031189015
   PubMedGoogle Scholar
• Leung CK-S, Cheung CYL, Weinreb RN, et al. Evaluation of retinal nerve fiber layer progression in glaucoma: a study on optical coherence tomography guided progression analysis. Invest Ophthalmol Vis Sci. 2010;51(1):217–222. doi:10.1167/iovs.09-3468
   PubMed Web of Science ®Google Scholar
• Amini N, Nowroozizadeh S, Cirineo N, et al. Influence of the disc–fovea angle on limits of rnfl variability and glaucoma discrimination. Invest Ophthalmol Vis Sci. 2014;55(11):7332–7342. doi:10.1167/iovs.14-14962
   PubMed Web of Science ®Google Scholar
• Kanamori A, Nakamura M, Escano MF, et al. Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography. Am J Ophthalmol. 2003;135(4):513–520. doi:10.1016/S0002-9394(02)02003-2
   PubMed Web of Science ®Google Scholar
• Kanamori A, Nakamura M, Matsui N, et al. Optical coherence tomography detects characteristic retinal nerve fiber layer thickness corresponding to band atrophy of the optic discs. Ophthalmology. 2004;111(12):2278–2283. doi:10.1016/j.ophtha.2004.05.035
   PubMed Web of Science ®Google Scholar
• Park KA, Kim YD, In woo K, et al. Optical coherence tomography measurements in compressive optic neuropathy associated with dysthyroid orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1617–1624. doi:10.1007/s00417-016-3335-9
   PubMed Web of Science ®Google Scholar
• Park KA, Kim YD, Woo KI. Changes in optical coherence tomography measurements after orbital wall decompression in dysthyroid optic neuropathy. Eye (Lond). 2018;32(6):1123–1129. doi:10.1038/s41433-018-0051-1
   PubMed Web of Science ®Google Scholar
• Cheng S, Yu Y, You Y, et al. Retinal nerve fiber layer thickness measured by optical coherence tomography predicts visual recovery after orbital decompression for dysthyroid optic neuropathy. Int Ophthalmol. 2021;41(9):3121–3133. doi:10.1007/s10792-021-01877-z
   PubMed Web of Science ®Google Scholar
• Gillespie EF, Smith TJ, Douglas RS. Thyroid eye disease: towards an evidence base for treatment in the 21st century. Curr Neurol Neurosci Rep. 2012;12(3):318–324. doi:10.1007/s11910-012-0256-9
   PubMed Web of Science ®Google Scholar
• Zang S, Ponto K, Pitz S, Kahaly G. Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy. J Endocrinol Invest. 2011;34:876–880. doi:10.1007/BF03346732
   PubMed Web of Science ®Google Scholar
• Blandford AD, Zhang D, Chundury RV, Perry JD. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017;12(2):111–121. doi:10.1080/17469899.2017.1276444
   PubMed Web of Science ®Google Scholar
• Bartalena L. Graves’ disease: complications. In: Feingold KR, Anawalt B, Boyce A, editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2021, MDText.com, Inc.; 2000.
   Google Scholar
• Perumal B, Meyer DR. Treatment of severe thyroid eye disease: a survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS). Ophthalmic Plast Reconstr Surg. 2015;31(2):127–131. doi:10.1097/IOP.0000000000000216
   PubMed Web of Science ®Google Scholar
• Ito M, Takahashi Y, Katsuda E, et al. Predictive factors of prognosis after radiation and steroid pulse therapy in thyroid eye disease. Sci Rep. 2019;9(1):2027. doi:10.1038/s41598-019-38640-5
   PubMed Web of Science ®Google Scholar
• Bartalena L, Krassas G, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–4463. doi:10.1210/jc.2012-2389
   PubMed Web of Science ®Google Scholar
• Mourits M, van Kempen-harteveld M, Garcia M, et al. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet. 2000;355:1505–1509. doi:10.1016/S0140-6736(00)02165-6
   PubMed Web of Science ®Google Scholar
• Prummel M, Terwee C, Gerding M, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15–20. doi:10.1210/jc.2003-030809
   PubMed Web of Science ®Google Scholar
• Gorman C, Garrity J, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’. Ophthal Ophthalmol. 2001;108:1523–1534. doi:10.1016/S0161-6420(01)00632-7
   PubMed Web of Science ®Google Scholar
• Rajendram R, Taylor P, Wilson V, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 x 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:299–309.
   PubMed Web of Science ®Google Scholar
• Prummel M, Mourits M, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet. 1993;342:949–954. doi:10.1016/0140-6736(93)92001-A
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14:853–860. doi:10.1007/BF03347943
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983;56:1139–1144.
   PubMed Web of Science ®Google Scholar
• McCord CD. Orbital decompression for Graves’ disease. Exposure through lateral canthal and inferior fornix incision. Ophthalmology. 1981;88(6):533–541. doi:10.1016/S0161-6420(81)34995-1
   PubMed Web of Science ®Google Scholar
• Leone CR, Bajandas FJ. Inferior orbital decompression for dysthyroid optic neuropathy. Ophthalmology. 1981;88(6):525–532.
   PubMed Web of Science ®Google Scholar
• Shorr N, Baylis HI, Goldberg RA, Perry JD. Transcaruncular approach to the medial orbit and orbital apex. Ophthalmology. 2000;107(8):1459–1463. doi:10.1016/S0161-6420(00)00241-4
   PubMed Web of Science ®Google Scholar
• Kazim M, Trokel SL, Acaroglu G, Elliott A. Reversal of dysthyroid optic neuropathy following orbital fat decompression. Br J Ophthalmol. 2000;84(6):600–605. doi:10.1136/bjo.84.6.600
   PubMed Web of Science ®Google Scholar
• Jacobs SM, McInnis CP, Kapeles M, Chang S-H. Incidence, risk factors, and management of blindness after orbital surgery. Ophthalmology. 2018;125(7):1100–1108. doi:10.1016/j.ophtha.2018.01.030
   PubMed Web of Science ®Google Scholar
• Kennedy DW, Goodstein ML, Miller NR, Zinreich SJ. Endoscopic transnasal orbital decompression. Arch Otolaryngol Head Neck Surg. 1990;116(3):275–282. doi:10.1001/archotol.1990.01870030039006
   PubMedGoogle Scholar
• Chu EA, Miller NR, Lane AP. Selective endoscopic decompression of the orbital apex for dysthyroid optic neuropathy. Laryngoscope. 2009;119(6):1236–1240. doi:10.1002/lary.20240
   PubMed Web of Science ®Google Scholar
• Farling PA. Thyroid disease. Br J Anaesth. 2000;85(1):15–28. doi:10.1093/bja/85.1.15
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl2):ii111–ii5. doi:10.1136/annrheumdis-2012-202576
   PubMed Web of Science ®Google Scholar
• Xie W, Huang Y, Xiao S, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048–1054. doi:10.1136/annrheumdis-2018-214846
   PubMed Web of Science ®Google Scholar
• Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol. 2012;83(9):1136–1145. doi:10.1016/j.bcp.2011.12.024
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402. doi:10.1016/S1473-3099(20)30132-8
   PubMed Web of Science ®Google Scholar
• Kaur K, Kalra S, Kaushal S. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther. 2014;36(7):1074–1086. doi:10.1016/j.clinthera.2014.06.018
   PubMed Web of Science ®Google Scholar
• Markham A. Baricitinib: first global approval. Drugs. 2017;77(6):697–704. doi:10.1007/s40265-017-0723-3
   PubMed Web of Science ®Google Scholar